Sanofi (SNY) Competitors

Sanofi logo
$47.12 -0.41 (-0.86%)
Closing price 04:00 PM Eastern
Extended Trading
$47.08 -0.04 (-0.08%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SNY vs. MRK, NVS, AZN, NVO, and PFE

Should you buy Sanofi stock or one of its competitors? Sanofi's main competitors and comparable companies include Merck & Co., Inc. (MRK), Novartis (NVS), AstraZeneca (AZN), Novo Nordisk A/S (NVO), and Pfizer (PFE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Sanofi compare to Merck & Co., Inc.?

Sanofi (NASDAQ:SNY) and Merck & Co., Inc. (NYSE:MRK) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Sanofi has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.13, indicating that its stock price is 87% less volatile than the broader market.

14.0% of Sanofi shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sanofi has a net margin of 8.70% compared to Merck & Co., Inc.'s net margin of 3.64%. Merck & Co., Inc.'s return on equity of 16.73% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
Sanofi8.70% 15.16% 8.48%
Merck & Co., Inc. 3.64%16.73%5.88%

Merck & Co., Inc. has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanofi$49.35B2.34$8.84B$2.0223.53
Merck & Co., Inc.$65.01B5.42$18.25B$0.97147.43

In the previous week, Merck & Co., Inc. had 32 more articles in the media than Sanofi. MarketBeat recorded 39 mentions for Merck & Co., Inc. and 7 mentions for Sanofi. Merck & Co., Inc.'s average media sentiment score of 0.80 beat Sanofi's score of 0.64 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sanofi
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Merck & Co., Inc.
23 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
5 Negative mention(s)
2 Very Negative mention(s)
Positive

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.7%. Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.4%. Sanofi pays out 87.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. pays out 350.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has raised its dividend for 14 consecutive years. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

Sanofi presently has a consensus price target of $53.00, indicating a potential upside of 11.51%. Merck & Co., Inc. has a consensus price target of $155.74, indicating a potential upside of 8.90%. Given Sanofi's higher possible upside, equities analysts plainly believe Sanofi is more favorable than Merck & Co., Inc..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sanofi
0 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.48
Merck & Co., Inc.
1 Sell rating(s)
11 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.59

Summary

Merck & Co., Inc. beats Sanofi on 11 of the 19 factors compared between the two stocks.

How does Sanofi compare to Novartis?

Sanofi (NASDAQ:SNY) and Novartis (NYSE:NVS) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sanofi presently has a consensus price target of $53.00, suggesting a potential upside of 11.51%. Novartis has a consensus price target of $152.25, suggesting a potential downside of 4.30%. Given Sanofi's stronger consensus rating and higher possible upside, equities research analysts clearly believe Sanofi is more favorable than Novartis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sanofi
0 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.48
Novartis
3 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.17

Sanofi has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Novartis has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

Novartis has a net margin of 18.11% compared to Sanofi's net margin of 8.70%. Novartis' return on equity of 41.04% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
Sanofi8.70% 15.16% 8.48%
Novartis 18.11%41.04%14.45%

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.7%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. Sanofi pays out 87.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis pays out 58.8% of its earnings in the form of a dividend.

In the previous week, Novartis had 15 more articles in the media than Sanofi. MarketBeat recorded 22 mentions for Novartis and 7 mentions for Sanofi. Sanofi's average media sentiment score of 0.64 beat Novartis' score of 0.56 indicating that Sanofi is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sanofi
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Novartis
6 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanofi$49.35B2.34$8.84B$2.0223.53
Novartis$54.53B5.57$13.98B$5.2430.36

Summary

Novartis beats Sanofi on 10 of the 19 factors compared between the two stocks.

How does Sanofi compare to AstraZeneca?

AstraZeneca (NYSE:AZN) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

AstraZeneca pays an annual dividend of $2.17 per share and has a dividend yield of 1.2%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.7%. AstraZeneca pays out 30.7% of its earnings in the form of a dividend. Sanofi pays out 87.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

AstraZeneca has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca$58.74B4.81$10.23B$7.0725.77
Sanofi$49.35B2.34$8.84B$2.0223.53

AstraZeneca has a net margin of 17.68% compared to Sanofi's net margin of 8.70%. AstraZeneca's return on equity of 31.85% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
AstraZeneca17.68% 31.85% 13.62%
Sanofi 8.70%15.16%8.48%

AstraZeneca has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

In the previous week, AstraZeneca had 13 more articles in the media than Sanofi. MarketBeat recorded 20 mentions for AstraZeneca and 7 mentions for Sanofi. AstraZeneca's average media sentiment score of 0.73 beat Sanofi's score of 0.64 indicating that AstraZeneca is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AstraZeneca
11 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Positive
Sanofi
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

AstraZeneca currently has a consensus price target of $206.67, indicating a potential upside of 13.41%. Sanofi has a consensus price target of $53.00, indicating a potential upside of 11.51%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts plainly believe AstraZeneca is more favorable than Sanofi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca
0 Sell rating(s)
3 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.84
Sanofi
0 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.48

20.4% of AstraZeneca shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

AstraZeneca beats Sanofi on 14 of the 19 factors compared between the two stocks.

How does Sanofi compare to Novo Nordisk A/S?

Sanofi (NASDAQ:SNY) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, Novo Nordisk A/S had 27 more articles in the media than Sanofi. MarketBeat recorded 34 mentions for Novo Nordisk A/S and 7 mentions for Sanofi. Sanofi's average media sentiment score of 0.64 beat Novo Nordisk A/S's score of 0.30 indicating that Sanofi is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sanofi
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Novo Nordisk A/S
16 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
5 Negative mention(s)
4 Very Negative mention(s)
Neutral

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.7%. Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 2.0%. Sanofi pays out 87.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S pays out 20.7% of its earnings in the form of a dividend.

Sanofi has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Novo Nordisk A/S has lower revenue, but higher earnings than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanofi$49.35B2.34$8.84B$2.0223.53
Novo Nordisk A/S$46.80B3.88$15.51B$3.9710.24

Sanofi presently has a consensus price target of $53.00, suggesting a potential upside of 11.51%. Novo Nordisk A/S has a consensus price target of $59.44, suggesting a potential upside of 46.23%. Given Novo Nordisk A/S's higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sanofi
0 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.48
Novo Nordisk A/S
5 Sell rating(s)
16 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.00

Novo Nordisk A/S has a net margin of 33.99% compared to Sanofi's net margin of 8.70%. Novo Nordisk A/S's return on equity of 53.52% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
Sanofi8.70% 15.16% 8.48%
Novo Nordisk A/S 33.99%53.52%19.49%

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Novo Nordisk A/S beats Sanofi on 10 of the 19 factors compared between the two stocks.

How does Sanofi compare to Pfizer?

Pfizer (NYSE:PFE) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Sanofi has a net margin of 8.70% compared to Pfizer's net margin of 6.34%. Pfizer's return on equity of 19.88% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
Pfizer6.34% 19.88% 8.52%
Sanofi 8.70%15.16%8.48%

In the previous week, Pfizer had 40 more articles in the media than Sanofi. MarketBeat recorded 47 mentions for Pfizer and 7 mentions for Sanofi. Sanofi's average media sentiment score of 0.64 beat Pfizer's score of 0.37 indicating that Sanofi is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pfizer
16 Very Positive mention(s)
7 Positive mention(s)
14 Neutral mention(s)
8 Negative mention(s)
2 Very Negative mention(s)
Neutral
Sanofi
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Sanofi has lower revenue, but higher earnings than Pfizer. Sanofi is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$62.58B2.59$7.77B$0.7040.58
Sanofi$49.35B2.34$8.84B$2.0223.53

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.1%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.7%. Pfizer pays out 245.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi pays out 87.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Pfizer presently has a consensus target price of $30.32, indicating a potential upside of 6.73%. Sanofi has a consensus target price of $53.00, indicating a potential upside of 11.51%. Given Sanofi's stronger consensus rating and higher probable upside, analysts plainly believe Sanofi is more favorable than Pfizer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pfizer
2 Sell rating(s)
14 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.18
Sanofi
0 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.48

Pfizer has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.6% of Pfizer shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Sanofi beats Pfizer on 10 of the 19 factors compared between the two stocks.

Get Sanofi News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNY vs. The Competition

MetricSanofiPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$115.23B$13.38B$7.60B$11.72B
Dividend Yield3.71%2.58%2.47%4.48%
P/E Ratio9.0727.9733.5830.13
Price / Sales2.326.798.275.60
Price / Cash6.7315.6321.0121.90
Price / Book1.365.394.443.72
Net Income$8.84B$2.88B$3.50B$393.88M
7 Day Performance-2.70%-5.24%-6.53%-6.07%
1 Month Performance16.03%-4.80%-4.93%-7.38%
1 Year Performance-6.99%-7.35%-1.73%-7.48%

Sanofi Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNY
Sanofi
4.271 of 5 stars
$47.12
-0.9%
$53.00
+12.5%
-8.2%$115.23B$49.35B9.0774,846
MRK
Merck & Co., Inc.
4.6417 of 5 stars
$144.49
-2.2%
$155.74
+7.8%
+53.9%$362.27B$65.01B47.1075,000
NVS
Novartis
3.3025 of 5 stars
$160.02
-0.3%
$152.25
-4.9%
+20.9%$305.78B$54.53B18.0375,267
AZN
AstraZeneca
4.774 of 5 stars
$183.96
-0.3%
$206.67
+12.3%
+1.9%$285.96B$58.74B18.2296,100
NVO
Novo Nordisk A/S
3.9695 of 5 stars
$41.60
-0.1%
$59.44
+42.9%
-16.2%$181.50B$46.80B10.4569,505

Related Companies and Tools


This page (NASDAQ:SNY) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners